BackInhibrx Biosciences Overview

Inhibrx Biosciences Total Liabilities

Track Inhibrx Biosciences's total liabilities ($210M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Total Liabilities
$207.20M
↑ 44.33% YoYΔ $63.64M vs prior year quarter

Peer trimmed avg / median

Loading

Inhibrx Biosciences Total Liabilities History

Loading

Inhibrx Biosciences vs. peers: Total Liabilities Comparison

Loading

Inhibrx Biosciences Total Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Inhibrx Biosciences (INBX) FAQ

As of the most recent data (June 2026), INBX shows a total liabilities of $210M. That compares with $140M in the prior-year period — up 44.3% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, INBX's total liabilities is now $210M (was $140M) — a 44.3% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Inhibrx Biosciences is outperforming or lagging.

Tracking INBX's total liabilities over time shows whether Inhibrx Biosciences is scaling, shrinking, or reshaping that part of the business. The current reading is $210M That compares with $140M in the prior-year period — up 44.3% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this total liabilities page, Stockcircle has Inhibrx Biosciences's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect total liabilities (currently $210M) with ownership activity and broader fundamentals.

Inhibrx Biosciences's total liabilities is $210M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.